Saint Egreve

Researchers are evaluating the effects of transcranial direct current stimulation tDCS on cannabis use disorder in people with schizophrenia. This study aims to see if 10 sessions of specific brain stimulation can reduce cannabis consumption, craving, addiction severity, and schizophrenia symptoms, while improving overall functioning. The study also explores possible changes in cognitive functions and brain connectivity related to these effects. Participants will receive either active tDCS or sham non-active stimulation using a Neurocan DC-Stimulator Plus device. Electrodes will be placed on the scalp to stimulate specific brain areas twice daily for 20 minutes each session over 5 consecutive weekdays. The control group will undergo a sham procedure that mimics the sensations of active stimulation without therapeutic effects. During the study, researchers will monitor cannabis use and craving scores at 3 and 6 months, hospitalizations, and brain connectivity changes through imaging studies. Participants will be assessed for schizophrenia symptoms and overall functioning. The study involves random assignment to treatment groups and double-blind masking to ensure unbiased results. Total involvement includes follow-up visits and evaluations over a 6-month period.

Researchers are evaluating the French validation of the Schizophrenia Proneness Instrument for Children and Youth SPI-CY to improve early detection of psychosis risk in adolescents aged 12 to 17. This approach focuses on identifying subtle early symptoms that may predict the later development of psychosis during the prodromal phase. The study aims to assess how reliably clinicians can use the French SPI-CY by comparing ratings between trained clinicians. All participants will undergo the SPI-CY interview conducted by a trained clinician. The study compares the initial clinicians SPI-CY rating with a second clinicians blind rating based on recorded interviews to test inter-rater reliability. Researchers will also explore connections between SPI-CY results and other clinical assessments, including the Comprehensive Assessment of At Risk Mental State CAARMS, Multisensory Hallucination Scale MHASC, Prodromal Questionnaire 16 PQ-16, Perceptual and Cognitive Aberrations PCA, and the Audiograph. Participants will be assessed with the SPI-CY on the first day, followed by secondary assessments within 15 days. The study involves audio-recorded interviews of SPI-CY administration with consent from adolescents and at least one parent. Researchers will use these assessments to measure the consistency of the SPI-CY tool and its relationship to other psychosis risk scales. The study is expected to last until February 2027, with no masking or placebo controls involved.